English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Will Parental Vaccine Hesitancy Retard the Embrace of Life-Saving Newborn Genetic Screening and Emerging Gene Therapy Revolution?
In these days of the never-ending pandemic, other health problems continue to take a backseat. That’s especially true for the 7,000 or so rare diseases that collectively affect only one in ten people, while the number of COVID fatalities in the US nears the million mark.
Although some clinical trials for rare disease treatments have stalled, they’ll resume once COVID settles into some version of endemicity. More than 60 cell and gene therapy FDA approvals are expected by 2030, according to the Massachusetts Institute of Technology’s New Drug Delivery Paradigms Initiative. They range from RNA-based drugs to gene therapies to CRISPR fixes.
CRISPR is tackling sickle cell disease and thalassemia, while antisense technology is being tried for Duchenne muscular dystrophy. Searching for “gene therapy” brings up 5000 hits for this older approach, many targeting childhood diseases.
BookmarkRelated Content
-
STR1VE-EU Trial Shows Efficacy of Onasemnogene Abeparvovec in Spinal Muscular AtrophyOnasemnogene abeparvovec gene replacemen...
-
Sofia’s Story – Johns Hopkin’sOn the morning of Friday, Aug. 23, 2019,...
-
New Components for Antisense Gene Therapy Show Promise in Treating Spinal Muscular AtrophySkoltech researchers and their colleague...
-
An Experimental Gene Therapy Was Little Alissa’s Only HopeThomas Feldborg and Daria Rokina set off...
-
Implications of Circulating Neurofilaments for Spinal Muscular Atrophy Treatment Early In Life: A Case SeriesThis longitudinal cohort study aimed to ...
-
Newborn Screening, Treatment Make Big Difference With Rare Muscle DisorderMateo Medina has never walked or talked....
-
Baby First at UNC to Receive Gene Therapy for SMA, Thanks to Early Check Newborn ScreeningIt was a pregnancy that went relatively ...
Powered by
In partnership with
